🐺 Does Colossal Biosciences’ dire wolf creation justify its $10B+ valuation? /// TechCrunch

Given the common startup tendency to overstate capabilities, it wasn’t easy to take Lamm’s claims at face value, particularly since Colossal’s ambitious de-extinction projects for the woolly mammoth and Tasmanian tiger were not slated for completion until 2028.

Spoiler alert: no. While there may be some interesting conservation applications here, I feel like the money and science could be put to much better use elsewhere.